





















































































































































































































































When	 making	 medical	 and	 policy	 decisions,	 including	 the	 introduction	 of	 early	 interventions	 and	
services,	the	burden	of	a	disorder	in	terms	of	mortality,	comorbidity,	disability	and	effects	on	the	quality	





A	strong	consensus	of	scientific	opinion	emphasizes	 the	negative	 impact	of	OCD	on	the	quality	of	 life,	
wellbeing	and	global	functioning	of	affected	patients	and	their	related	caregivers	(Macy	et	al.,	2013).	A	
number	of	studies	have	examined	quality	of	life	(QoL)	in	OCD	and	several	comprehensive	reviews	have	
been	 carried	 out	 (Coluccia	 et	 al.,	 2016;	Macy	 et	 al.,	 2013;	 Subramaniam	 et	 al.,	 2013;	 among	 others).	
Patients	 with	 OCD	 show	 a	 poorer	 QoL	 than	 healthy	 controls	 and	 the	 population	 in	 general.	 Further,	
when	OCD	has	been	compared	with	other	mental	or	physical	conditions,	some	studies,	although	not	all,	
have	 found	 that	 the	 effects	 of	 OCD	 on	 QoL	 are	 similar	 to	 those	 of	 serious	 mental	 illnesses	 such	 as	
schizophrenia	 (Macy	 et	 al.,	 2013;	 Subramaniam	et	 al.,	 2013).	 The	QoL	domains	most	 affected	 in	OCD	
include	 social	 relationships,	 including	 emotional	 and	 psychological	 components.	 Physical	 domains,	
although	impaired,	are	usually	less	affected.		
	Two	 key	 factors	 reported	 to	 influence	 QoL	 in	 OCD	 include	 disease	 severity	 and	 comorbidity.	 The	
association	 between	 OCD	 severity	 and	 QoL	 impairment	 is	 seen	 to	 affect	 even	 subclinical	 samples	
(Fullana	 et	 al.,	 2009,	 Fineberg	 et	 al.,	 2013a).	 Comorbid	 conditions,	 such	 as	 anxiety	 disorders,	 mood	
disorders	 or	 OC	 related	 disorders	 (OCRDs),	 which	 are	 very	 frequent	 in	 OCD	 patients,	 have	 a	 highly	
significant	 impact	 on	 lowering	QoL.	 Importantly,	 treatment	 studies	 have	 shown	 that	 improvement	 in	
OCD	is	associated	with	an	increase	in	QoL.	Hollander	and	colleagues	(2010)	showed	that	disability	and	
QoL	 significantly	 improved	 in	 patients	 showing	 a	 positive	 symptomatic	 treatment-response,	 and	 was	
significantly	better	compared	to	non-responders	or	those	who	experienced	a	relapse.	Therefore,	OCD,	
even	 at	 subclinical	 levels,	 involves	 a	 substantial	 decrease	 in	 QoL,	 which	 significantly	 improves	 with	
effective	treatment	and	improvement	of	the	condition.	
	
Studies	 focusing	 on	 disability	 have	 also	 demonstrated	 the	 substantial	 impact	 of	 OCD.	 Wittchen	 and	
colleagues	(2011)	examined	the	disability	adjusted	life	years	lost	(DALY)	associated	with	a	broad	range	of	
mental	 and	 neurological	 illnesses	 in	 Europe.	 Although	 the	 study	 reported	 a	 lower	 prevalence	 of	OCD	
(0.7%)	 than	 is	 usually	 reported	 in	 epidemiological	 studies,	 OCD	 accounted	 for	 329,684	 DALYs,	 which	
means	a	rate	of	7.9	DALYs	per	10,000	persons,	i.e.	higher	than	that	reported	in	epilepsy	(6.9),	although	
lower	 than	 that	 of	 unipolar	 depression	 (10.3),	 which	 showed	 the	 highest	 disability.	 Indeed,	 the	 high	
rates	 of	 comorbidity	 usually	 existing	 between	 OCD	 and	 depression	 suggests	 that	 those	 with	 both	
conditions,	who	may	show	even	higher	levels	of	disability	than	those	with	‘pure’	illness,	might	have	been	
included	 in	 the	depression	group	only,	 thus	underestimating	 the	 true	 impact	of	OCD.	Rates	of	under-
employment	 ranging	 from	 22%	 to	 as	 high	 as	 38%	 have	 been	 reported	 among	 OCD	 subjects	 in	
community	 and	 clinical	 samples	 (Mancebo	 et	 al.,	 2008).	 Early	 intervention	 could	 thus	 be	 expected	 to	
reduce	burden	and	costs	of	OCD,	for	example,	by	treating	frequently	co-occurring	depression	early.	
	
Although	 research	 into	 the	costs	of	 treated	and	untreated	OCD	 is	 scarce,	 the	existing	data	emphasise	
the	 significant	 indirect	 costs	 of	 OCD,	 such	 as	 loss	 of	 employment	 productivity,	 and	 the	 highly	 cost-
effective	impact	of	effective	treatment	(Hollander	et	al.,	2016).	For	example,	historical	data	estimating	
the	 1990	 total	 costs	 of	 OCD	 in	 the	 USA	 found	 that	 indirect	 costs,	 reflecting	 lost	 productivity	 of	
individuals	suffering	from	residual	OCD,	represented	74%	of	the	total	economic	cost	of	OCD	(Dupont	et	
al.,	1995).	Another	analysis	by	Knapp	and	colleagues	(2002),	which	examined	health	service	utilization,	
including	 mental	 health	 expenditure,	 inpatient	 hospitalization	 and	 ambulatory	 services,	 other	 formal	
care	 services,	 lost	 employment	 and	 education,	 family	 and	 caregiver	 impact,	 mortality,	 and	 transfer	
payments,	concluded	that	the	economic	consequences	of	OCD	were	widespread,	long	lasting,	and	often	
profound,	 involving	not	only	the	direct	costs	of	treatments	and	health	services	utilization,	but	also	the	
indirect	 effects	 on	 personal	 income,	 the	 ability	 to	 work,	 productive	 contributions	 to	 the	 national	
economy	and	impoverishment	of	quality	of	life.		
	
Preliminary	studies	using	health	economic	modelling	have	suggested	 that	 the	 treatment	of	OCD	using	
standard	 pharmacological	 or	 psychological	 therapies,	 or	 their	 combination,	 is	 cost-effective.	 Two	
analyses	(Skapinakis	et	al.,	2016b,	Fineberg	et	al.,	2018)	estimated	that	SSRIs	represented	the	most	cost-
effective	 option,	 whereas	 the	 other	 (National	 Institute	 for	 Health	 and	 Clinical	 Excellence,	 2006),	
estimated	that	the	combined	option	was	the	most	cost-effective.	Further	studies	designed	to	test	real-










































































Despite	 the	 availability	 of	 effective	 treatments	 for	 OCD	 (Hirschtritt	 et	 al.,	 2017),	 the	 treatment	 gap	
(difference	 between	 individuals	 with	 OCD	 needing	 treatment	 and	 those	 actually	 receiving	 it)	 was	
estimated,	 in	Europe,	 to	stand	at	25%	of	cases	 in	2004	(50%	approximately	 in	 the	world)	 (Kohn	et	al.,	
2004).	The	proportion	of	subjects	not	being	treated	worldwide	 in	more	recent	epidemiological	studies	
was	estimated	to	vary	between	22	and	92%,	with	38-to-90%	of	individuals	not	even	seeking	treatment	
or	advice	 (Garcia-Soriano	et	al.,	2014).	 	 In	 those	patients	with	OCD	receiving	 treatment,	 the	extended	
DUI	can	be	attributed	to	 long	delays	 in	actively	seeking	help	 (e.g.	 the	mean	 interval	between	disorder	




However,	 the	 interval	 between	 help	 seeking	 and	 receiving	 an	 adequate	 treatment	 for	 OCD	 is	 also	
significant	 (approximately	 2	 years	 for	 pharmacological	 treatment	 (Strengler	 et	 al.,	 2013;	 Albert	 et	 al.	
2018a)).	 This	 means	 that	 there	 is	 difficulty	 for	 physicians	 and/or	 mental	 health	 professionals	 in	
recognizing	and	diagnosing	OCD	appropriately	(high	rates	of	OCD	symptom	misidentification	by	mental	
health	 professionals	 were	 found	 (Glazier	 et	 al.,	 2013)),	 or	 in	 prescribing	 or	 offering	 an	 adequate	
treatment	 (it	 may	 be	 that	 psychological	 therapies	 other	 than	 CBT	 with	 exposure	 and	 response	
prevention	are	applied,	or	that	antidepressants	other	than	clomipramine	or	SSRIs	are	prescribed,	or	for	








severe	 symptoms.	 It	 may	 be	 speculated	 that	 the	 DUI	 in	 OCD	 promotes	 neuroprogression	 or	
neurodegeneration,	 as	 hypothesized	 for	 psychosis	 (Anderson	 et	 al.,	 2014).	 Studies	 demonstrating	 an	
association	between	 longer	duration	of	OCD	and	either	 reduced	hippocampal	and	amygdalar	volumes	
(Atmaca	 et	 al.,	 2008)	 or	 reduced	N-acetyl	 aspartate	 among	 other	 neurochemical	measures	 in	 several	
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